NorthStar Trial Analysis at ELCC 2026: Local Consolidative Therapy in EGFR-Mutant NSCLC

oncodaily - The management of metastatic EGFR-mutant non-small cell lung cancer (NSCLC) has been transformed by the introduction of third-generation EGFR tyrosine kinase inhibitors, particularly osimertinib. While systemic therapy achieves meaningful disease […]

AI Summary: ELCC 2026 brought together clinicians and investigators to present pivotal lung‑cancer studies, including localized consolidative therapy, SBRT sequencing with immunotherapy, and trials addressing under‑represented KRAS and EGFR populations. The conference highlighted survival and tumor‑control signals, networked international collaborators, and emphasized real‑world applicability — proving once again that conferences are where hope meets peer review.


At ELCC: late‑breaking trials reshaping clinical practice

4 months / oncodaily

4 months / oncodaily

5 months / oncodaily

5 months / oncodaily

5 months / oncodaily

5 months / oncodaily


OTHER: misc lung oncology studies, regulatory and surgical updates

4 months / medicalxpress

4 months / oncodaily

4 months / nature

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / medicalxpress


Precision push: molecular testing, KRAS degraders, ADC collaborations advancing care

4 months / oncodaily

4 months / medicalxpress

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily


Voices from ELCC: clinicians share breakthroughs and practical takeaways

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

5 months / oncodaily

5 months / oncodaily

5 months / oncodaily

5 months / oncodaily

5 months / oncodaily

5 months / oncodaily


All Other Stories

4 months / oncodaily

4 months / oncodaily

4 months / nature

4 months / medicalxpress

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / medicalxpress

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily

4 months / oncodaily





Related Stories


AACR launches Rare Cancers Initiative to accelerate research collaboration / 5 wks

AstraZeneca deal to bring sunvozertinib to US expands access for EGFR Exon20 patients / 6 wks

Phase I lung cancer trials consolidating at top-performing U.S. sites / 4 months

ENZAMET trial confirms long-term survival benefit of enzalutamide in mHSPC / 8 days

Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 1 month

Teclistamab shows survival benefit prompting earlier use discussions / 2 months

CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 4 months

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Weight Loss, Supplements, Digital Health, Autism and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.